AbbVie Inc. reported solid second quarter 2023 financial performance on 27 July, with US biosimilar erosion for Humira a bit lower than the company projected while immunology successors Skyrizi and Rinvoq showed strong growth and price stabilization in the US. But CEO Rick Gonzalez pointed to one of AbbVie’s struggling core products, Imbruvica, as one that could be a target of the first Medicare price negotiations this fall under the Inflation Reduction Act (IRA).
Imbruvica (ibrutinib), a BTK inhibitor partnered with Johnson & Johnson, posted a 25% revenue decline during Q1 due to...








